Insight

Photo from National Foundation for Cancer Research

Aug 6, 2024, 06:07

Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib

Lungevity Foundation shared a recent article by Yi-Long Wu, commenting:

“What’s after osimertinib for pts with EGFR+ NSCLC? Researchers are working on options… just released. primary analysis of the phase 2 INSIGHT 2 study of tepotinib, a highly selective MET inhibitor, combined with osimertinib at EGFR Resisters and EGFR Positive UK.”

Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, also added:

“Tepotinib plus osimertinib in EGFR+ and NSCLC with MET amp following progression on first-line osimertinib (INSIGHT 2).

ORR 50% (56.6% if MET GCN >10; 42.2% if <10)

mPFS 5.6 mo; mOS 17.8 mo

On target resistance after combo in 34% pts

Title: Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Author: Yi-Long Wu , Valentina Guarneri , Pei Jye Voon , Boon Khaw Lim , Jin-Ji Yang , Marie Wislez , Cheng Huang, Chong Kin Liam , Julien Mazieres , Lye Mun Tho , Hidetoshi Hayashi , Nguyen Viet Nhung , Puey Ling Chia , Filippo de Marinis , Jo Raskin , Qinghua Zhou , Giovanna Finocchiaro , Anh Tuan Le , Jialei Wang , Christophe Dooms , Terufumi Kato , Ernest Nadal , How Soon Hin , Egbert F Smit , Martin Wermke , Daniel Tan , Masahiro Morise , Aurora O’Brate , Svenja Adrian , Boris M Pfeiffer , Christopher Stroh , Dilafruz Juraeva , Rainer Strotmann , Kosalaram Goteti , Karin Berghoff, Barbara Ellers-Lenz , Niki Karachaliou , Xiuning Le , Tae Min Kim ; INSIGHT 2 investigators

Primary analysis

Source: Lungevity Foudation/X and Biagio Ricciuti/X

Biagio Ricciuti cancer Dana-Farber Cancer Institute Lungevity Foudation OncoDaily Oncology osimertinib Pei Jye Voon Primary analysis Tae Min Kim Valentina Guarneri Xiuning Le Yi-Long Wu

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage